Loading clinical trials...

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE) | Clinical Trials | Clareo Health

COMPLETED

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

A Prospective Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in China

NCT05221580•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The purpose of this study is to collect information on how Ryzodeg® works in real-world patients. Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•2. The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on the approved Ryzodeg® label in China and independently from the decision to include the patient in this study.
•3. Male or female, age above or equal to 18 years at the time of signing informed consent.
•4. Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 20 weeks prior to Treatment Initiation Visit (Visit 1).
•5. Available and documented Glycosylated haemoglobin (HbA1c) value below or equal to 12 weeks prior to Informed Consent and Treatment Initiation Visit (Visit 1).

Exclusion Criteria

•1. Previous participation in this study. Participation is defined as having given informed consent in this study.
•2. Treatment with any investigational drug within 30 days prior to enrolment into the study.
•3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•4. Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the approved Ryzodeg® label in China.

Locations (50)

NIS-The Second People's Hospital of Hefei

Hefei, Anhui, China

NIS-Beijing Hospital

Beijing, Beijing Municipality, China

NIS-Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

NIS-People's Hospital of Chongqing Banan District

Chongqing, Chongqing Municipality, China

NIS-Gansu Provincial People's Hospital

Lanzhou, Gansu, China

NIS-The people's hospital of JiangMen

Jiangmen, Guangdong, China

NIS-2nd Affiliated Hospital of Shantou University Medical

Shantou, Guangdong, China

NIS-Shenzhen Longgang District People's Hospital

Shenzhen, Guangdong, China

NIS-Yangjiang People's Hospital

Yangjiang, Guangdong, China

NIS-The First People's Hospital of Yulin City

Yulin, Guangxi, China

Key Dates

Start Date

March 18, 2022

Primary Completion Date

March 31, 2023

Completion Date

March 31, 2023

Last Updated

June 14, 2024

Enrollment

887

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

Ryzodeg®

DRUG

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 14, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)